Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia, Psychiatric, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 7/29/2018 |
| Start Date: | September 15, 2017 |
| End Date: | October 2022 |
| Contact: | Lawrence Kegeles, MD, Ph.D. |
| Email: | lsk5@columbia.edu |
| Phone: | 646-774-5560 |
Schizophrenia (SZ) is a highly debilitating neuropsychiatric disorder of young adulthood
onset and a leading cause of disability worldwide. While treatments delivered at early stages
of the disorder may be effective at reducing psychosis or altering the course of the disease,
there are currently no biomarkers capable of identifying subjects in early stages of SZ who
are likely to respond to treatment and would be good candidates for available proactive,
symptomatic or future disease-modifying treatments; or those who would not respond and can be
spared unnecessary medication exposure. The lack of these vitally important biomarkers
provides a compelling rationale for the present multidisciplinary research project, which
aims to develop and validate highly promising noninvasive and objective proton magnetic
resonance spectroscopy (1H MRS)-based biomarkers for monitoring treatment response in early
stages of SZ. In support of the viability of this overall objective is a large body of data,
reported by the applicants and others, that show (a) that levels of glutamate (Glu) and -
aminobutyric acid (GABA) - respectively, the major excitatory and inhibitory amino acid
neurotransmitter systems - are abnormally elevated in medication-naïve and unmedicated first
episode and chronic SZ patients; (b) that the effect of treatment with antipsychotic
medications in these populations may be to lower or normalize brain levels of both Glu and
GABA. To investigate the potential of these in vivo brain Glu and GABA abnormalities to serve
as biomarkers of treatment response in early-stage SZ, the applicants propose to use 1H MRS
to measure Glu and GABA levels in the largest cohort of medication-free SZ subjects to date,
at baseline and following 4 weeks of antipsychotic treatment.
onset and a leading cause of disability worldwide. While treatments delivered at early stages
of the disorder may be effective at reducing psychosis or altering the course of the disease,
there are currently no biomarkers capable of identifying subjects in early stages of SZ who
are likely to respond to treatment and would be good candidates for available proactive,
symptomatic or future disease-modifying treatments; or those who would not respond and can be
spared unnecessary medication exposure. The lack of these vitally important biomarkers
provides a compelling rationale for the present multidisciplinary research project, which
aims to develop and validate highly promising noninvasive and objective proton magnetic
resonance spectroscopy (1H MRS)-based biomarkers for monitoring treatment response in early
stages of SZ. In support of the viability of this overall objective is a large body of data,
reported by the applicants and others, that show (a) that levels of glutamate (Glu) and -
aminobutyric acid (GABA) - respectively, the major excitatory and inhibitory amino acid
neurotransmitter systems - are abnormally elevated in medication-naïve and unmedicated first
episode and chronic SZ patients; (b) that the effect of treatment with antipsychotic
medications in these populations may be to lower or normalize brain levels of both Glu and
GABA. To investigate the potential of these in vivo brain Glu and GABA abnormalities to serve
as biomarkers of treatment response in early-stage SZ, the applicants propose to use 1H MRS
to measure Glu and GABA levels in the largest cohort of medication-free SZ subjects to date,
at baseline and following 4 weeks of antipsychotic treatment.
Inclusion Criteria (Patients):
1. Male or females between the ages of 18-35
2. less than five years (<60 months) of active Diagnostic and Statistical Manual of
Mental Disorders (DSM) diagnosis of schizophrenia, schizophreniform, or
schizoaffective disorder
3. Capacity to provide informed consent
4. No major medical or neurological illness
5. Medication free (3 weeks without antipsychotic medications)
Exclusion Criteria (Patients):
1. Current alcohol or drug abuse (<1 month) or substance dependence (<6 months) or
substances used within one day of the imaging study.
2. Pregnant or lactating women or women of child-bearing potential, who are either not
surgically-sterile or, for outpatients, not using appropriate methods of birth
control.
3. Intelligence Quotient (IQ) <70
4. Acute risk for suicide or violence
5. Presence of pacemaker or any metallic objects in the body that would interfere with
the MRS or cause MRI safety problems
6. Claustrophobia
7. Any organic brain disorder (including epilepsy, mental retardation, or a medical
condition whose pathology or treatment would likely alter the presentation or
treatment of SZ
8. Individuals on anti-epileptic medications (e.g., valproate, carbamazepine) that may
affect GABA or Glu
9. Unstable medical or neurological condition
10. DSM-V diagnosis of bipolar disorder I
11. DSM-V diagnosis of major depression with psychotic features
12. History of non-response to or non-tolerance of Risperidone
Inclusion Criteria (Healthy Controls)
1. Male or females between the ages of 18-35
2. less than five years (<60 months) of active DSM diagnosis of schizophrenia,
schizophreniform, or schizoaffective disorder
3. No major medical or neurological illness
Exclusion Criteria (Healthy Controls)
1. Current alcohol or drug abuse (<1 month) or substance dependence (<6 months) or
substances used within one day of the imaging study.
2. Pregnant or lactating women or women of child-bearing potential, who are either not
surgically-sterile or, for outpatients, not using appropriate methods of birth
control.
3. IQ<70
4. Acute risk for suicide or violence
5. Presence of pacemaker or any metallic objects in the body that would interfere with
the MRS or cause MRI safety problems
6. Claustrophobia
7. History of psychotropic medication use such as antipsychotics or antidepressants
8. Any first-degree family history of psychotic illness
9. Personal history of any DSM Axis I disorder
10. Individuals on anti-epileptic medications (e.g., valproate, carbamazepine) that may
affect GABA or Glu
11. Unstable medical or neurological condition
12. Any organic brain disorder (including epilepsy, mental retardation, or a medical
condition whose pathology or treatment would likely alter the presentation or
treatment of SZ
We found this trial at
2
sites
New York, New York 10032
Principal Investigator: Lawrence Kegeles, MD, PhD
Phone: 646-774-5560
Click here to add this to my saved trials
Click here to add this to my saved trials